.
rocketvax, SARS-CoV-2

23 June 2021

“New vaccine should protect longer” – BZ Basel is reporting about RocketVax’s SARS-CoV-2 vaccine

The University Hospital Basel (USB), the University of Basel, and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research collaboration with the startup company RocketVax. The goal is to develop a next-generation vaccine against Covid-19 that will provide better protection against viral mutants and elicit a longer-term immune response. The collaboration is embedded in the existing, close and productive research collaboration between the three institutions.

RocketVax is developing a vaccine based on a complete but genetically modified virus. Unlike most existing vaccines, the new model is designed to present a large spectrum of viral components to the immune system, eliciting a broader, longer-term stable immune response than most current vaccines, which use only a single viral protein. The virus has a built-in defect (deletion) that cannot be repaired, and therefore can only undergo a single cycle of replication, preventing it from causing disease.

To read the full article published by BZ Basel, open the document below:

bz_2021-06-15.pdf

Source: BZ Basel

Share

23 July 2021

BZ Basel: “One step closer to new vaccine: human testing next year”

“RocketVax, a Basel-based company, has cleared another hurdle in the production of its new vaccine. It should protect longer and better against the coronavirus, as well as be able to be delivered all over the world.” BZ Basel is reporting about RocketVax’s SARS-CoV-2 vaccine. To read the full article, open the document below: BZ_Basel_20210716 Source: […]

29 June 2021

Bajour: “Big Pharma brings the power, startups provide the creativity”

Bajour is reporting about the creativity and potential of startup pharma companies. Among others, they presented the RocketVax project, the second-generation SARS-CoV-2 vaccine, led by Prof. Dr. Thomas Klimkait. To read the full article, click on the link below: bajour.pdf Source: bajour.ch Share

22 June 2021

BaZ: “Basel government approves one million for coronavirus vaccine”

“The Basel government is getting involved in the development of another vaccine against Covid-19. The government approved a CHF 1 million grant from the local development fund to support the preclinical development of a vaccine from the Basel-based start-up RocketVax. RocketVax, founded in the summer of 2020 and headquartered in Basel, is a subsidiary of […]

18 June 2021

BZ Basel: On behalf of the Basel start-up RocketVax, Prof. Dr. Thomas Klimkait is developing a new type of coronavirus vaccine

Basel University Hospital, the University of Basel, and the Swiss Tropical and Public Health Institute have agreed to collaborate with the company RocketVax and jointly advance research to develop a novel vaccine against the SARS-CoV-2 coronavirus. BZ Basel published an article on Prof. Dr. Thomas Klimkait, our Project Leader in Vaccine Design and Preclinical Virology. […]

28 May 2021

Prof. Dr. Manuel Battegay, Head of the Department of Infectious Diseases & Hospital Epidemiology at University Hospital Basel, spoke about the current Coronavirus situation

Prof. Dr. Manuel Battegay is Head of the Department of Infectious Diseases & Hospital Epidemiology at University Hospital Basel. In his interview for the University of Basel, he gave his expert’s opinion on some actual questions related to the COVID-19 pandemic and coronavirus vaccines such as:   How can we prevent severe cases of coronavirus infection?   Should healthy […]